Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Free Cash Flow (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Free Cash Flow for 11 consecutive years, with $508.4 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 248.57% to $508.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 311.46% year-over-year, with the annual reading at $1.1 billion for FY2025, 269.0% up from the prior year.
  • Free Cash Flow for Q4 2025 was $508.4 million at BeOne Medicines, up from $312.2 million in the prior quarter.
  • The five-year high for Free Cash Flow was $508.4 million in Q4 2025, with the low at -$689.4 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$195.2 million, with a median of -$272.7 million recorded in 2022.
  • The sharpest move saw Free Cash Flow crashed 534.7% in 2022, then surged 580.23% in 2025.
  • Over 5 years, Free Cash Flow stood at -$94.0 million in 2021, then plummeted by 534.7% to -$596.3 million in 2022, then decreased by 13.35% to -$675.9 million in 2023, then soared by 49.38% to -$342.2 million in 2024, then soared by 248.57% to $508.4 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $508.4 million, $312.2 million, and $262.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.